Predictive factors of radiation therapy for patients with prostate specific antigen recurrence after radical prostatectomy

BJU International

Volumn 90, Issue 9, 2002, Pages 887-892

  De La Taille, A ^a,c   Flam, T A ^a   Thiounn, N ^a   Pontvert, D ^b   Saighi, D ^a   Zerbib, M ^a   Debre B ^a  

^a CHU Cochin ^*  (France)

^b INSTITUT CURIE   (France)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Prognostic factors; Prostate cancer; PSA recurrence; Radiation therapy; Radical prostatectomy

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FOLLOW UP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIMODALITY CANCER THERAPY; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SALVAGE THERAPY; SCORING SYSTEM; TREATMENT FAILURE; ADJUVANT THERAPY; BLOOD; DISEASE FREE SURVIVAL; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0036884447     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.2002.03055.x     Document Type: Article

References (33)

1. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7
2. Oesterling JE. Prostate specific antigen, a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-23
3. Partin AW, Pearson JD, Landis PK et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 1994; 43: 649-59
4. Vanuytsel L, Janssens G, Van Poppel H, Rijnders A, Baert L. Radiotherapy for PSA recurrence after radical prostatectomy. Eur Urol 2001; 39: 425-9
5. Nudell DM, Grossfeld GD, Weinberg VK et al. Radiotherapy after radical prostatectomy: treatment outcomes and failure patterns. Urology 1999; 54: 1049-52
6. Garg MK, Tekyi-Mensah S, Bolton S et al. Impact of postprostatectomy prostate-specific antigen nadir on outcomes following salvage radiotherapy. Urology 1998; 51: 998-1002
7. Pisansky TM, Kozelsky TF, Myers RP et al. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000; 163: 845-50
8. Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998; 41: 735-40
9. Wu JJ, King SC, Montana GS, McKinstry CA, Anscher MS. The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 1995; 32: 317-23
10. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: early versus delayed treatment. J Urol 1994; 151: 1575-8
11. Haab F, Meulemans A, Boccon-Gibod L et al. Effect of radiation therapy after radical prostatectomy on serum prostate-specific antigen measured by an ultrasensitive assay. Urology 1995; 45: 1022-7
12. Coetzee LJ, Hars V, Paulson DF. Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. Urology 1996; 47: 232-5
13. Medini E, Medini I, Reddy PK, Levitt SH. Delayed/salvage radiation therapy in patients with elevated prostate specific antigen levels after radical prostatectomy. A long term follow-up. Cancer 1996; 78: 1254-9
14. Schild SE, Buskirk SJ, Wong WW et al. The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 1996; 156: 1725-9
15. Crane CH, Rich TA, Read PW, Sanfilippo NJ, Gilienwater JY, Kelly MD. Preirradiation PSA predicts biochemical disease-free survival in patients treated with postprostatectomy external beam irradiation. Int J Radiat Oncol Biol Phys 1997; 39: 681-6
16. Forman JD, Meetze K, Pontes E et al. Therapeutic irradiation for patients with an elevated post-prostatectomy prostate specific antigen level. J Urol 1997; 158: 1436-9
17. Morris MM, Dallow KC, Zietman AL et al. Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 731-6
18. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 1997; 49: 65-70
19. Do T, Parker RG, Do C, Tran L, Do L, Dolkar D. Salvage radiotherapy for biochemical and clinical failures following radical prostatectomy. Cancer J Sci Am 1998; 4: 324-30
20. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159: 173-7
21. Grossfeld GD, Tigrani VS, Nudell D et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 2000; 164: 93-9
22. Leibovich BC, Engen DE, Patterson DE et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 2000; 163: 1178-82
23. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19: 1030-9
24. Gibbons RP, Cole BS, Richardson RG et al. Adjuvant radiotherapy following radical prostatectomy, results and complications. J Urol 1986; 135: 65-8
25. D'Amico AV, Whittington R, Malkowicz SB et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131-8
26. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-93
27. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995; 154: 1818-24
28. Epstein JI. Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol 1990; 14: 626-32
29. Anscher MS, Robertson CN, Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 1995; 33: 37-41
30. Valicenti RK, Gomella L. G., Ismail, M et al. The efficacy of early adjuvant radiation therapy for pT3NO prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1999; 45: 53-5
31. Formenti SC, Lieskovsky G, Simoneau AR et al. Impact of moderate dose of postoperative radiation on urinary continence and potency in patients with prostate cancer treated with nerve sparing prostatectomy. J Urol 1996; 155: 616-9
32. Jacobson GM, Smith JA Jr. Stewart JR, Postoperative radiation therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 1987; 13: 1021-4
33. Pilepich MV, Walz BJ, Baglan RJ. Postoperative irradiation in carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984; 10: 1869-73